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Reply 
To the Editor: 
In my review of Fig. 1, there appears to be a small 
by systematic bias of the predicted erythromycin breath 
results over 1 hour (i.e., ERMBT l-hour values) dur- 
ing conditions of extreme inhibition (i.e., at very low 
ERMBT 20-minute measured values). Thus, equation 
4 will improve the interpretation of the breath test. 
However, upon further reflection, is there really a need 
for such a conversion? It appears that calculation of 
ERMBT has changed over the years from an AUC 
determination over 135 minutes,’ to one over 60 min- 
utes,2-4 to a single breath test at 20 minutes.526 With a 
half-life of 1 to 2 hours, the ERMBT (in any of these 
forms) does not represent the clearance of ery- 
thromycin. Instead, the significance of ERMBT deter- 
mination lies with its ability to measure hepatic CYP3A 
activity. Because a good correlation is found between 
20minute ERMBT values and l-hour ERMBT values, 
why not just simply report the 20minute ERMBT val- 
ues and avoid the conversion altogether? I believe that 
this would make more sense, be an easier approach, and 
would still allow for treatment comparisons within a 
subject by representing the data as percentage of con- 
trol. For treatment comparisons between subjects, both 
methods (i.e., 20minute ERMBT values or conversion 
to l-hour ERMBT values) would have the same advan- 
tages and disadvantages. 
With respect to the article by Cheng et a1.,7 upon 
reanalysis using equation 4, the results were essentially 
the same. For example, the mean + SD values of para- 
meter estimates for inhibition of ERMBT by delavir- 
dine plasma concentrations were (compare with Table 
VI in Cheng et a1.7): predose ERMBT of 2.85% f 
1.16% t‘XJ exhaled/hr (3.1-fold range), I,,, of 84.5% 
+ 5.2% inhibition (1.3-fold range), and IC,, of 0.933 
kO.854 pmol/L (49.5-fold range). Updated figures and 
tables are available on request. It should be appreciated 
that all of our original conclusions remain intact. 
David E. Smith, PhD 
Upjohn Center for Clinical Pharmacology 
University of Michigan 
Ann Arbol; Mich. 
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